Opaleye Management Inc.'s Form 4 filing
Grace Therapeutics, Inc.GRCE · filed Oct 26, 2026
- Accession no.
- 0001493152-26-048591
- Filed
- Oct 26, 2026, 6:06 PM ET
- Trade date
- Oct 22-26, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $158.6K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Opaleye Management Inc.CIK 0001595855 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 22, 2026 | Common Stock, par value $0.0001 per share | PPurchaseAcquired | +21,390 | $1.93F2 | +$41,192.86 | 2,970,000 | Indirect | |
| Oct 26, 2026 | Common Stock, par value $0.0001 per share | PPurchaseAcquired | +66,411 | $1.77F3 | +$117,408.01 | 3,036,411 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.91 to $1.93. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.705 to $1.79. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.
Referenced by the price of 1 transaction in Table I.